Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
Conditions
Interventions
bimekizumab
Locations
2
United States
UP0119 2
Glendale, California, United States
UP0119 1
Berlin, Germany
Start Date
March 17, 2022
Primary Completion Date
January 9, 2023
Completion Date
January 9, 2023
Last Updated
April 10, 2025
NCT06679413
NCT05845645
NCT04867642
NCT04828343
NCT04444466
NCT04136444
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions